Table 6.
Biomarkers b,c | Overall mortality
|
Cancer-specific mortality
|
Tumor progression
|
|||
---|---|---|---|---|---|---|
HR | P | HR | P | HR | P | |
PTEN | 1.00 (0.99–1.01) | .73 | 1.00 (0.99–1.01) | .97 | 1.00 (0.99–1.01) | .38 |
phos-AKT | 0.28 (0.05–1.68) | .16 | 0.01 (0.01–6.61) | .13 | 0.22 (0.02–2.55) | .22 |
phos-S6 | 1.00 (0.99–1.02) | .73 | 1.01 (0.99–1.03) | .38 | 1.01 (0.99–1.03) | .45 |
phos-4EBP1 | 1.00 (0.99–1.01) | .84 | 1.00 (0.99–1.01) | .43 | 1.00 (0.99–1.01) | .92 |
p27 | 1.01 (1.00–1.02) | .19 | 1.01 (0.99–1.03) | .35 | 1.01 (1.00–1.03) | .05 |
HIF-1α | 1.01 (0.99–1.04) | .37 | 1.02 (0.98–1.05) | .44 | 1.01 (0.97–1.04) | .68 |
Values provided correspond to hazard ratios (HRs) with 95% CIs in parenthesis. Each marker was entered separately.
Adjusted for T stage, Fuhrman grade, and tumor size.
HRs for c-MYC were excluded due to extremely low values.